Oculis Holding AG (OCS) Total Non-Current Liabilities (2021 - 2026)
Oculis Holding AG (OCS) recorded quarterly Total Non-Current Liabilities of $4.4 million in Q1 2026, up 12.97% quarter-over-quarter from $3.9 million in Q4 2025, and up 91.01% on a YoY basis from $2.3 million in Q1 2025.
Oculis Holding AG (OCS) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends
Oculis Holding AG's Total Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $4.4 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 91.01% year-over-year to $4.4 million; the TTM figure through Mar 2026 stood at $4.4 million (up 91.01% YoY), while the FY2025 annual figure was $3.9 million, up 26.08% from the prior year.
- Total Non-Current Liabilities was $4.4 million for Q1 2026 at Oculis Holding AG, up from $3.9 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $127.7 million in Q4 2022 to a low of $938676.2 in Q2 2023.
- Historically, Total Non-Current Liabilities has averaged $12.3 million across 5 years, with a median of $2.5 million in 2024.
- The sharpest annual moves came in 2023 and 2024: Total Non-Current Liabilities tumbled 98.64% in 2023, then surged 167.65% in 2024.
- A 5-year view of Total Non-Current Liabilities shows it stood at $127.7 million in 2022, then sank by 98.64% to $1.7 million in 2023, then surged by 80.18% to $3.1 million in 2024, then increased by 26.08% to $3.9 million in 2025, then increased by 12.97% to $4.4 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $4.4 million (Q1 2026), $3.9 million (Q4 2025), and $4.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 42,980.09 |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 64.76 Mn |
| 10 | Oculis Holding AG | 8.23 Bn | 7.92 Bn | - | 4.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.45 Mn |
| Dec 31, 2025 | 3.94 Mn |
| Sep 30, 2025 | 4.39 Mn |
| Jun 30, 2025 | 2.39 Mn |
| Mar 31, 2025 | 2.33 Mn |
| Dec 31, 2024 | 3.12 Mn |
| Sep 30, 2024 | 3.07 Mn |
| Jun 30, 2024 | 2.51 Mn |
| Mar 31, 2024 | 1.75 Mn |
| Dec 31, 2023 | 1.73 Mn |
| Sep 30, 2023 | 1.34 Mn |
| Jun 30, 2023 | 938,676.16 |
| Dec 31, 2022 | 127.71 Mn |
| Dec 31, 2021 | 124.65 Mn |